Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

FDA Panel Votes Down Selinexor for Multiple Myeloma

In an 8-to-5 vote, the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending accelerated approval of selinexor for...

How I Treat In Brief: Treating the Young Patient With Multiple Myeloma

Recently, Sara Gandolfi, MD; Claudia Paba Prada, MD; and Paul G. Richardson, MD, discussed the treatment of younger patients with multiple myeloma, balancing disease...

ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma

Results from the phase II ELOQUENT-3 trial demonstrate that the combination of elotuzumab plus pomalidomide and dexamethasone extended progression-free survival (PFS) compared with pomalidomide...

Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma

New results from the large phase III Myeloma XI trial confirm that maintenance therapy with lenalidomide improves progressionfree survival (PFS) over observation alone in...

BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma

In a first-in-human trial published in Lancet Oncology, the anti–B-cell maturation antigen (BCMA) antibody GSK2857916 was associated with clinical activity and was reasonably well...

Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial

For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT), a standard salvage therapy approach involves high-dose chemotherapy and...

Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma

Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome inhibitor (PI) ixazomib in patients with newly diagnosed multiple...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab responded to treatment with melflufen, according to interim data...

Selinexor Induces Deep Responses in Refractory Multiple Myeloma

More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a combination of selinexor and low-dose dexamethasone, according to results...
WIB_icon

Can a Selinexor Combination STOMP Out Relapsed/Refractory Multiple Myeloma?

The combination of selinexor plus low-dose bortezomib and dexamethasone produced high response rates in patients with relapsed or refractory multiple myeloma (MM), with a...

SHARE